PriceTargets.com logo

Eiger BioPharmaceuticals - EIGR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $120.00
  • Forecasted Upside: ∞
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 04/10/2024 05:00 PM ET
+0 (0.00%)

This chart shows the closing price for EIGR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Eiger BioPharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EIGR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EIGR

Analyst Price Target is $120.00
▲ +∞ Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Eiger BioPharmaceuticals in the last 3 months. The average price target is $120.00, with a high forecast of $150.00 and a low forecast of $90.00. The average price target represents a ∞ upside from the last price of $0.00.

This chart shows the closing price for EIGR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Eiger BioPharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/29/2023CitigroupLower TargetBuy ➝ Buy$120.00 ➝ $90.00Low
6/30/2023Robert W. BairdBoost TargetOutperform$90.00 ➝ $150.00Low
12/12/2022BTIG ResearchLower Target$1,440.00 ➝ $270.00Low
12/9/2022Robert W. BairdLower Target$870.00 ➝ $90.00Low
12/9/2022CitigroupLower Target$690.00 ➝ $120.00Low
9/7/2022BTIG ResearchLower TargetBuy$1,710.00 ➝ $1,440.00Low
8/9/2021CitigroupBoost TargetBuy$780.00 ➝ $810.00High
8/6/2021BTIG ResearchReiterated RatingBuy$1,350.00High
5/11/2021CitigroupBoost Target$690.00 ➝ $780.00Medium
1/19/2021WedbushReiterated RatingBuy$660.00Medium
9/29/2020LADENBURG THALM/SH SHReiterated RatingBuy$840.00Medium
9/1/2020WedbushReiterated RatingBuy$960.00High
6/4/2020WedbushReiterated RatingBuy$1,020.00High
4/3/2020WedbushReiterated RatingBuy$1,050.00 ➝ $990.00High
3/24/2020WedbushReiterated RatingOutperformMedium
1/22/2020LADENBURG THALM/SH SHBoost TargetBuy$840.00 ➝ $930.00Low
1/6/2020WedbushReiterated RatingBuy$1,050.00Low
12/16/2019Gilford SecuritiesInitiated CoverageAverageMedium
11/11/2019LADENBURG THALM/SH SHReiterated RatingBuy$840.00High
8/12/2019LADENBURG THALM/SH SHReiterated RatingBuy$840.00High
6/26/2019KeyCorpInitiated CoverageOverweight$660.00 ➝ $321.60Low
6/26/2019CitigroupInitiated CoverageBuy$660.00 ➝ $660.00Low
6/18/2019WedbushReiterated RatingOutperform$1,050.00Low
6/18/2019LADENBURG THALM/SH SHReiterated RatingBuy$840.00High
5/16/2019WedbushReiterated RatingBuy$1,050.00Low
4/24/2019WedbushLower TargetOutperform$1,290.00 ➝ $1,050.00Low
(Data available from 4/24/2019 forward)

News Sentiment Rating

-0.04 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Eiger BioPharmaceuticals logo
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $4.94
Low: $1.30
High: $7.17

52 Week Range

Now: N/A

Volume

137,800 shs

Average Volume

103,866 shs

Market Capitalization

$2.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.83

Frequently Asked Questions

What sell-side analysts currently cover shares of Eiger BioPharmaceuticals?

The following sell-side analysts have issued research reports on Eiger BioPharmaceuticals in the last twelve months: Citigroup Inc., Robert W. Baird, and StockNews.com.
View the latest analyst ratings for EIGR.

What is the current price target for Eiger BioPharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Eiger BioPharmaceuticals in the last year. Their average twelve-month price target is $120.00. Robert W. Baird has the highest price target set, predicting EIGR will reach $150.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $90.00 for Eiger BioPharmaceuticals in the next year.
View the latest price targets for EIGR.

What is the current consensus analyst rating for Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EIGR will outperform the market and that investors should add to their positions of Eiger BioPharmaceuticals.
View the latest ratings for EIGR.

What other companies compete with Eiger BioPharmaceuticals?

Other companies that are similar to Eiger BioPharmaceuticals include 9 Meters Biopharma, Pulmatrix, Gamida Cell, Eloxx Pharmaceuticals and Altamira Therapeutics. Learn More about companies similar to Eiger BioPharmaceuticals.

How do I contact Eiger BioPharmaceuticals' investor relations team?

Eiger BioPharmaceuticals' physical mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company's listed phone number is (650) 272-6138 and its investor relations email address is [email protected]. The official website for Eiger BioPharmaceuticals is www.eigerbio.com. Learn More about contacing Eiger BioPharmaceuticals investor relations.